Molecular Biology of Pituitary Carcinoma and Aggressive Pituitary Neuroendocrine Tumors: A Contemporary Review

Abstract

Aggressive pituitary neuroendocrine tumors (PitNETs/APTs) and pituitary carcinomas (PCs) represent distinct clinical challenges characterized by profound heterogeneity regarding clinical presentation, proliferative markers, and therapeutic response. Importantly, approximately half of these neoplasms manifest an aggressive clinical course only years subsequent to an initially indolent or apparently benign presentation. While APTs and PCs share overlapping phenotypic and histopathological properties, a Ki67 proliferation index >10% and extensive p53 expression are significantly more prevalent in carcinomas. At the genomic level, somatic mutations within TP53 and ATRX constitute the most frequent genetic alterations, making their early molecular detection a potentially invaluable tool for identifying aggressive behavior prior to overt clinical progression. These underlying oncogenic drivers encompass chromosomal and genomic instability, compromised DNA repair machinery, cell cycle dysregulation, epigenetic aberrations, altered intracellular signaling cascades, and remodeling of the tumor immune microenvironment Elucidating the intricate mechanisms driving pituitary tumorigenesis is critical for developing effective therapeutic strategies specific to these refractory subtypes, which are classically characterized by local invasiveness, high proliferative indices, frequent relapse, and resistance to conventional treatments. Although novel systemic modalities, specifically VEGF-targeted agents and immune checkpoint inhibitors, have been deployed with heterogeneous clinical efficacy, the clinical management of these tumors remains constrained by limited therapeutic options. Therefore, the systematic histopathological and molecular analysis of established prognostic markers must be comprehensively integrated into routine clinical practice.